Jonathan D Licht

List of Publications by Year
in descending order

331 papers	24,757 citations	9264 74 h-index	7518 151 g-index
342 all docs	342 docs citations	342 times ranked	31064 citing authors

#	Article	IF	Citations
1	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	16.8	2,328
2	MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456, 980-984.	27.8	2,111
3	Deconstructing a Disease: RARîœ€, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. Blood, 1999, 93, 3167-3215.	1.4	990
4	Mitochondria Are Required for Antigen-Specific T Cell Activation through Reactive Oxygen Species Signaling. Immunity, 2013, 38, 225-236.	14.3	981
5	Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 2003, 34, 148-150.	21.4	960
6	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
7	Transcription Factors, Normal Myeloid Development, and Leukemia. Blood, 1997, 90, 489-519.	1.4	684
8	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl. Nature, 1997, 389, 187-190.	27.8	509
9	Histone deacetylase inhibitors in cancer therapy. Cancer Cell, 2003, 4, 13-18.	16.8	451
10	Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends in Cell Biology, 2006, 16, 45-54.	7.9	408
11	Sprouty1 Is a Critical Regulator of GDNF/RET-Mediated Kidney Induction. Developmental Cell, 2005, 8, 229-239.	7.0	327
12	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood, 2011, 117, 211-220.	1.4	300
13	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 2009, 114, 3448-3458.	1.4	292
14	Sprouty1 Regulates Reversible Quiescence of a Self-Renewing Adult Muscle Stem Cell Pool during Regeneration. Cell Stem Cell, 2010, 6, 117-129.	11.1	275
15	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine, 2004, 10, 1329-1335.	30.7	272
16	Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 2009, 114, 2764-2773.	1.4	259
17	Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. Molecular Cell, 2003, 12, 1551-1564.	9.7	251
18	Drosophila KrÃ¼ppel protein is a transcriptional represser. Nature, 1990, 346, 76-79.	27.8	250

#	Article	IF	Citations
19	The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling. Molecular Cell, 2013, 51, 236-248.	9.7	244
20	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
21	Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation. Journal of Biological Chemistry, 2001, 276, 46460-46468.	3.4	225
22	Translocations of the RARÎ± gene in acute promyelocytic leukemia. Oncogene, 2001, 20, 7186-7203.	5.9	206
23	Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports, 2018, 25, 2808-2820.e4.	6.4	201
24	Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. Molecular and Cellular Biology, 2002, 22, 1804-1818.	2.3	200
25	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
26	Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis. Molecular and Cellular Biology, 2003, 23, 8992-9002.	2.3	198
27	Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud Morphogenesis. Developmental Cell, 2009, 17, 199-209.	7.0	193
28	Targeting Epigenetics in Cancer. Annual Review of Pharmacology and Toxicology, 2018, 58, 187-207.	9.4	185
29	Transcription Factors, Normal Myeloid Development, and Leukemia. Blood, 1997, 90, 489-519.	1.4	183
30	Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation. PLoS Genetics, 2014, 10, e1004566.	3.5	178
31	Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene, 1999, 18, 925-934.	5.9	177
32	The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 2008, 111, 3145-3154.	1.4	176
33	Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3624-3629.	7.1	169
34	AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene, 2001, 20, 5660-5679.	5.9	168
35	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 2000, 20, 6550-6567.	2.3	167
36	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	2.3	164

#	Article	IF	Citations
37	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Medicine, 2012, 18, 1118-1122.	30.7	162
38	Sequence-specific DNA Binding and Transcriptional Regulation by the Promyelocytic Leukemia Zinc Finger Protein. Journal of Biological Chemistry, 1997, 272, 22447-22455.	3.4	161
39	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature, 2021, 589, 299-305.	27.8	155
40	WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins. Journal of Biological Chemistry, 1995, 270, 10878-10884.	3.4	148
41	A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports, 2013, 3, 1449.	3.3	146
42	Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Developmental Biology, 2006, 299, 466-477.	2.0	141
43	Kidney Development in the Absence of Gdnf and Spry1 Requires Fgf10. PLoS Genetics, 2010, 6, e1000809.	3.5	139
44	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2000, 20, 2075-2086.	2.3	134
45	Cloning and Characterization of a Novel Mouse AP-2 Transcription Factor, Ap-2Î´, with Unique DNA Binding and Transactivation Properties. Journal of Biological Chemistry, 2001, 276, 40755-40760.	3.4	133
46	CTNNB1 Mutations and Overexpression of Wnt/Î²-Catenin Target Genes in WT1-Mutant Wilms' Tumors. American Journal of Pathology, 2004, 165, 1943-1953.	3.8	130
47	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelialâ€“mesenchymal transition and invasive properties of prostate cancer. Oncogene, 2013, 32, 2882-2890.	5.9	130
48	A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. Blood, 1999, 94, 3737-3747.	1.4	129
49	Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13549-13554.	7.1	129
50	Epigenetic regulation of normal and malignant hematopoiesis. Oncogene, 2007, 26, 6697-6714.	5.9	127
51	Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia, 2014, 28, 198-201.	7.2	122
52	The Role of Nuclear Receptorâ€“Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026708.	6.2	122
53	Physical and Functional Interactions of Human Endogenous Retrovirus Proteins Np9 and Rec with the Promyelocytic Leukemia Zinc Finger Protein. Journal of Virology, 2007, 81, 5607-5616.	3.4	121
54	Growth Suppression by Acute PromyelocyticLeukemia-Associated Protein PLZF Is Mediated by Repression ofc-mycExpression. Molecular and Cellular Biology, 2003, 23, 9375-9388.	2.3	120

#	Article	IF	Citations
55	Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2249-2253.	7.1	118
56	Tyrosine Phosphorylation of Sprouty Proteins Regulates Their Ability to Inhibit Growth Factor Signaling: A Dual Feedback Loop. Molecular Biology of the Cell, 2004, 15, 2176-2188.	2.1	118
57	Leukemia-associated retinoic acid receptor Â fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10255-10260.	7.1	115
58	E-cadherin Is a WT1 Target Gene. Journal of Biological Chemistry, 2000, 275, 10943-10953.	3.4	112
59	SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant. Cancer Research, 2004, 64, 5556-5559.	0.9	107
60	miR-27b controls venous specification and tip cell fate. Blood, 2012, 119, 2679-2687.	1.4	107
61	Emerging Epigenetic Targets and Therapies in Cancer Medicine. Cancer Discovery, 2012, 2, 405-413.	9.4	106
62	UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Reports, 2017, 21, 628-640.	6.4	106
63	A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene, 2018, 37, 1911-1925.	5.9	102
64	Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 2002, 9, 322-332.	2.5	101
65	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2005, 25, 5552-5566.	2.3	99
66	HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. Journal of Clinical Investigation, 2010, 120, 1535-1550.	8.2	98
67	Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARÎ± fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 1999, 18, 1113-1118.	5.9	97
68	Deregulation of H3K27 methylation in cancer. Nature Genetics, 2010, 42, 100-101.	21.4	97
69	Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2462-71.	7.1	96
70	WT1 Activates a Glomerular-Specific Enhancer Identified from the Human Nephrin Gene. Journal of the American Society of Nephrology: JASN, 2004, 15, 2851-2856.	6.1	94
71	Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity. Immunity, 2009, 30, 802-816.	14.3	88
72	PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes and Development, 2009, 23, 2076-2087.	5.9	87

#	Article	IF	Citations
73	WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck. Molecular Cancer Research, 2015, 13, 293-304.	3.4	82
74	ATF-2 controls transcription of Maspin and GADD45Î± genes independently from p53 to suppress mammary tumors. Oncogene, 2008, 27, 1045-1054.	5.9	77
75	GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Scientific Reports, 2015, 5, 9489.	3.3	77
76	Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?. Cancer Cell, 2006, 9, 73-74.	16.8	76
77	Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancerâ€"Different Paths, Same Destination. Clinical Cancer Research, 2014, 20, 5001-5008.	7.0	75
78	HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research, 2019, 25, 5686-5701.	7.0	75
79	MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene, 2016, 35, 5905-5915.	5.9	74
80	MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia, 2013, 27, 686-694.	7.2	73
81	The WT1 Wilms' tumor suppressor gene: How much do we really know?. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 1-28.	7.4	72
82	The Receptor Tyrosine Kinase Regulator Sprouty1 Is a Target of the Tumor Suppressor WT1 and Important for Kidney Development. Journal of Biological Chemistry, 2003, 278, 41420-41430.	3.4	72
83	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood, 2004, 103, 1454-1463.	1.4	70
84	An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11154-11159.	7.1	68
85	The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Journal of Biological Chemistry, 2002, 277, 37045-37053.	3.4	67
86	BRCA1 Augments Transcription by the NF-Îº B Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit. Journal of Biological Chemistry, 2003, 278, 26333-26341.	3.4	67
87	HOX deregulation in acute myeloid leukemia. Journal of Clinical Investigation, 2007, 117, 865-868.	8.2	66
88	Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 2007, 14, 1802-1812.	11.2	65
89	A Mutation in Histone H2B Represents a New Class of Oncogenic Driver. Cancer Discovery, 2019, 9, 1438-1451.	9.4	65
90	WT1 Induces Apoptosis through Transcriptional Regulation of the Proapoptotic Bcl-2 Family Member Bak. Cancer Research, 2005, 65, 8174-8182.	0.9	64

#	Article	IF	Citations
91	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 1999, 18, 633-641.	5.9	59
92	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood, 2000, 96, 3939-3947.	1.4	59
93	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Research, 2019, 79, 2947-2961.	0.9	59
94	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
95	The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic Acids Research, 1999, 27, 4106-4113.	14.5	57
96	DNMT3A mutations in acute myeloid leukemia. Nature Genetics, 2011, 43, 289-290.	21.4	56
97	Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression. Molecular and Cellular Proteomics, 2016, 15, 776-790.	3.8	56
98	CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood, 2018, 132, 837-848.	1.4	56
99	BRCA1 Physically and Functionally Interacts with ATF1. Journal of Biological Chemistry, 2000, 275, 36230-36237.	3.4	55
100	DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension. Cell, 2015, 162, 938-939.	28.9	55
101	FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nature Communications, 2020, 11, 928.	12.8	54
102	Comprehensive genomic screens identify a role for PLZF-RARÎ± as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood, 2009, 114, 5499-5511.	1.4	53
103	The acute promyelocytic leukemiaâ€"associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D3â€"induced monocytic differentiation of U937 cells through a physical interaction with vitamin D3receptor. Blood, 2001, 98, 3290-3300.	1.4	52
104	miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia, 2013, 27, 344-352.	7.2	51
105	Elevated CK-MB with normal total creatine kinase in suspected myocardial infarction: Associated clinical findings and early prognosis. American Heart Journal, 1986, 111, 1041-1047.	2.7	49
106	The nucleus is irreversibly shaped by motion of cell boundaries in cancer and nonâ€cancer cells. Journal of Cellular Physiology, 2018, 233, 1446-1454.	4.1	49
107	USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. Blood, 2018, 132, 423-434.	1.4	49
108	Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clinical Cancer Research, 2003, 9, 2005-14.	7.0	49

#	Article	IF	Citations
109	H3K27 Methylation. Advances in Cancer Research, 2016, 131, 59-95.	5.0	48
110	Selective repression of transcriptional activators at a distance by the Drosophila KrÃ¼ppel protein. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11361-11365.	7.1	47
111	Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11422-11427.	7.1	47
112	WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene, 1999, 18, 417-427.	5.9	47
113	PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene, 2002, 21, 6669-6679.	5.9	46
114	Acute Promyelocytic Leukemia â€" Weapons of Mass Differentiation. New England Journal of Medicine, 2009, 360, 928-930.	27.0	46
115	Sprouty Proteins Inhibit Receptor-mediated Activation of Phosphatidylinositol-specific Phospholipase C. Molecular Biology of the Cell, 2010, 21, 3487-3496.	2.1	45
116	The Transcriptional Effect of WT1 Is Modulated by Choice of Expression Vector. Journal of Biological Chemistry, 1995, 270, 29976-29982.	3.4	44
117	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice and Research in Clinical Haematology, 2003, 16, 387-408.	1.7	44
118	Over-expression of Flt3 induces NF-Î°B pathway and increases the expression of IL-6. Leukemia Research, 2005, 29, 893-899.	0.8	43
119	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 2004, 103, 4650-4658.	1.4	42
120	Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. BMC Genomics, 2010, 11, 696.	2.8	41
121	The Molecular Pathology of Acute Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2005, 2005, 137-142.	2.5	40
122	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood, 2008, 112, 644-651.	1.4	40
123	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene, 2019, 38, 671-686.	5.9	39
124	Two N-Terminal Self-Association Domains Are Required for the Dominant Negative Transcriptional Activity of WT1 Denys-Drash Mutant Proteins. Biochemical and Biophysical Research Communications, 1997, 233, 723-728.	2.1	38
125	<i>Spry1</i>and<i>Spry2</i>Are Necessary for Lens Vesicle Separation and Corneal Differentiation. , 2011, 52, 6887.		38
126	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports, 2015, 12, 1300-1313.	6.4	37

#	Article	IF	Citations
127	Synergistic activity of Sef and Sprouty proteins in regulating the expression ofGbx2 in the mid-hindbrain region. Genesis, 2005, 41, 110-115.	1.6	36
128	Sprouty Proteins Are Negative Regulators of Interferon (IFN) Signaling and IFN-inducible Biological Responses. Journal of Biological Chemistry, 2012, 287, 42352-42360.	3.4	36
129	Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Current Opinion in Hematology, 2017, 24, 336-344.	2.5	36
130	Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochemical and Biophysical Research Communications, 2004, 316, 85-92.	2.1	35
131	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227.	5.5	35
132	The Effects of the Fanconi Anemia Zinc Finger (FAZF) on Cell Cycle, Apoptosis, and Proliferation Are Differentiation Stage-specific. Journal of Biological Chemistry, 2002, 277, 26327-26334.	3.4	33
133	Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e40-e40.	6.2	33
134	Widespread microRNA degradation elements in target mRNAs can assist the encoded proteins. Genes and Development, 2021, 35, 1595-1609.	5.9	33
135	Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Current Opinion in Hematology, 2005, 12, 7-13.	2.5	32
136	The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?. Journal of Clinical Oncology, 2005, 23, 3957-3970.	1.6	31
137	Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F. Clinical Cancer Research, 2010, 16, 4339-4352.	7.0	31
138	Ponatinibâ€"A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 5828-5834.	7.0	31
139	Tumor-associated WT1 Missense Mutants Indicate That Transcriptional Activation by WT1 Is Critical for Growth Control. Journal of Biological Chemistry, 1999, 274, 13258-13263.	3.4	29
140	The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein. Leukemia, 2002, 16, 1755-1762.	7.2	29
141	High-throughput gene screen reveals modulators of nuclear shape. Molecular Biology of the Cell, 2020, 31, 1392-1402.	2.1	29
142	New molecular concepts and targets in acute myeloid leukemia. Current Opinion in Hematology, 2008, 15, 82-87.	2.5	28
143	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leukemia and Lymphoma, 2015, 56, 2895-2901.	1.3	28
144	Two Evolutionarily Conserved Repression Domains in the <i>Drosophila KrÃ¼ppel</i> Protein Differ in Activator Specificity. Molecular and Cellular Biology, 1997, 17, 4820-4829.	2.3	26

#	Article	IF	Citations
145	Chromatin Modulation by Oncogenic Transcription Factors: New Complexity, New Therapeutic Targets. Cancer Cell, 2007, 11, 475-478.	16.8	26
146	From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma. Cancer Cell, 2014, 25, 9-11.	16.8	26
147	Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. Journal of Biological Chemistry, 2017, 292, 2237-2254.	3.4	26
148	Molecular characterization of acute myeloid leukemia and its impact on treatment. Current Opinion in Oncology, 2007, 19, 635-649.	2.4	24
149	Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics, 2021, 13, 115.	4.1	24
150	The PLZF Gene of t(11;17)-Associated APL. , 2007, 313, 31-48.		24
151	A Pathologic Link between Wilms Tumor Suppressor Gene, WT1, and IFI16. Neoplasia, 2008, 10, 69-IN29.	5.3	23
152	Epigenetic therapy of hematological malignancies: where are we now?. Therapeutic Advances in Hematology, 2013, 4, 81-91.	2.5	23
153	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	1.4	23
154	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Letters, 2020, 475, 99-108.	7.2	22
155	Spry1 and Spry2 are necessary for eyelid closure. Developmental Biology, 2013, 383, 227-238.	2.0	21
156	Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitorâ€"Induced DNA Damage and Apoptosis. Molecular Cancer Therapeutics, 2013, 12, 1591-1604.	4.1	21
157	Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood, 2009, 114, 153-156.	1.4	20
158	SETD2: a complex role in blood malignancy. Blood, 2017, 130, 2576-2578.	1.4	20
159	Computational Identification of Ftz/Ftz-F1 downstream target genes. Developmental Biology, 2006, 299, 78-90.	2.0	19
160	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
161	Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor Î± (PLZF-RARÎ±), an Oncogenic Transcriptional Repressor of Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) and Tumor Protein p53 (TP53) Genes. Journal of Biological Chemistry, 2014, 289, 18641-18656.	3.4	19
162	The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia, 2021, 35, 796-808.	7.2	19

#	Article	IF	Citations
163	Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia, 1999, 13, 1534-1538.	7.2	18
164	Targeting EZH2 in Multiple Myelomaâ€"Multifaceted Anti-Tumor Activity. Epigenomes, 2018, 2, 16.	1.8	18
165	MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncology, 2019, 98, 147-155.	1.5	18
166	Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemiaâ€"reperfusion injury. Basic Research in Cardiology, 2019, 114, 7.	5.9	18
167	WT1 Induction of Mitogen-Activated Protein Kinase Phosphatase 3 Represents a Novel Mechanism of Growth Suppression. Molecular Cancer Research, 2008, 6, 1225-1231.	3.4	17
168	Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell and Melanoma Research, 2020, 33, 507-514.	3.3	17
169	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discovery, 2022, 12, 186-203.	9.4	17
170	Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.. Blood, 2006, 108, 517-517.	1.4	17
171	The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme Î²-polymerase. Aids, 2001, 15, 433-440.	2.2	16
172	Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors. Journal of Biological Chemistry, 2013, 288, 23814-23822.	3.4	16
173	Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding. Journal of Biological Chemistry, 2019, 294, 12459-12471.	3.4	16
174	Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresisâ€"Top-Down Mass Spectrometry. Analytical Chemistry, 2021, 93, 5151-5160.	6.5	16
175	Regulation of CD4+ and CD8+ Effector Responses by Sprouty-1. PLoS ONE, 2012, 7, e49801.	2.5	16
176	G Protein-regulated Inducer of Neurite Outgrowth (GRIN) Modulates Sprouty Protein Repression of Mitogen-activated Protein Kinase (MAPK) Activation by Growth Factor Stimulation. Journal of Biological Chemistry, 2012, 287, 13674-13685.	3.4	15
177	Specific MicroRNA Deregulated in Myleoproliferative Neoplasm Are Regulated by JAK2V617F and May Contribute to Aberrant Hematopoiesis.. Blood, 2009, 114, 965-965.	1.4	15
178	Over-Expression of Flt3 Induces the Expression of NFkB Target Genes, cIAP-1 and IL-6.. Blood, 2004, 104, 2051-2051.	1.4	14
179	Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1994, 34, 79-80.	2.3	13
180	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal, 2011, 1, e7-e7.	6.2	13

#	Article	IF	Citations
181	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 2000, 20, 6550-6567.	2.3	13
182	Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival. Cancer, 1990, 66, 632-639.	4.1	12
183	Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 223-225.	2.3	12
184	New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy. Clinical Cancer Research, 2012, 18, 5163-5171.	7.0	12
185	EKLF and the Development of the Erythroid Lineage. , 0, , 71-84.		11
186	Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants. Oncogene, 2011, 30, 832-842.	5.9	11
187	Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood, 2012, 119, 5522-5531.	1.4	11
188	Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics and Chromatin, 2015, 8, 38.	3.9	11
189	Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS ONE, 2016, 11, e0162515.	2.5	11
190	Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogenâ€mediated changes in cell cycle regulatory circuits. Journal of Cellular Biochemistry, 2018, 119, 3267-3279.	2.6	11
191	Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. Oncogene, 2008, 27, 5260-5266.	5.9	10
192	MEK and MAF in myeloma therapy. Blood, 2011, 117, 2300-2302.	1.4	10
193	Oncogenesis by E2A-PBX1 in ALL: RUNX and more. Blood, 2020, 136, 3-4.	1.4	10
194	Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. FASEB Journal, 2017, 31, 482-490.	0.5	9
195	A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF. Blood, 1999, 94, 3737-3747.	1.4	9
196	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood, 2000, 96, 3939-3947.	1.4	9
197	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Clinical Cancer Research, 2022, 28, 756-769.	7.0	9
198	NGFIA (EGR1) Contains Transcription Activating Domains in Both the Amino Terminal and Carboxyl Terminal Regions of the Protein. Biochemical and Biophysical Research Communications, 1993, 194, 425-431.	2.1	8

#	Article	IF	Citations
199	Retinoid and growth factor receptor signaling in APL. Blood, 2005, 105, 1381-1382.	1.4	7
200	Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119047.	4.1	7
201	A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia. Blood, 2018, 132, 653-653.	1.4	7
202	Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors. Blood, 2014, 124, 611-611.	1.4	7
203	Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Diseaseâ€"Specific Death in Cancer Survivors. JAMA Network Open, 2022, 5, e2218183.	5.9	7
204	Genomic structure of the human PLZF gene. Gene, 1999, 236, 21-24.	2.2	6
205	A Comprehensive Genomic Approach Using Gain of Function Cell Models, Patient Specimens and ChIP-on-CHIP Technologies Identifies PLZF-RARÎ± Target Genes with Potential Roles in t(11;17) Associated APL.. Blood, 2007, 110, 3168-3168.	1.4	6
206	HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-Like Disease in Mice. SSRN Electronic Journal, 2018, , .	0.4	5
207	Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine. Journal of the American Society of Nephrology: JASN, 2019, 30, 1398-1411.	6.1	5
208	The role of sex and rurality in cancer fatalistic beliefs and cancer screening utilization in Florida. Cancer Medicine, 2021, 10, 6048-6057.	2.8	5
209	Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?. Journal of Clinical Investigation, 2001, 108, 1277-1278.	8.2	5
210	Integrative Analysis of Genomic Aberration and Gene Expression Suggests That MPD with Loss of Heterozygosity or Gain of Chromosome 9 Represents a Distinct Entity. Blood, 2008, 112, 3735-3735.	1.4	5
211	Partners in Crime: Genes within an Amplicon Collude to Globally Deregulate Chromatin in Lymphoma. Cancer Cell, 2010, 18, 539-541.	16.8	4
212	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. IScience, 2021, 24, 102651.	4.1	4
213	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. Blood, 2019, 134, 4407-4407.	1.4	4
214	<i>POU2AF1</i> As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma. Blood, 2020, 136, 18-19.	1.4	4
215	Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210. Journal of Negative Results in BioMedicine, 2004, 3, 7.	1.4	3
216	Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma.. Blood, 2004, 104, 5-5.	1.4	3

#	Article	IF	Citations
217	Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 437-437.	1.4	3
218	Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage. Blood, 2018, 132, 2643-2643.	1.4	3
219	Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. Molecular Cancer Therapeutics, 2022, 21, 511-521.	4.1	3
220	HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Therapy, 2022, 29, 1840-1846.	4.6	3
221	The BTB Domain Zinc Finger Proteins. , 2005, , 134-150.		2
222	Epigenetic Therapy. , 2018, , 1-1.		2
223	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. Blood, 2007, 110, 345-345.	1.4	2
224	Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma. Blood, 2018, 132, 189-189.	1.4	2
225	Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms. Blood, 2020, 136, 36-36.	1.4	2
226	t(8;21) AML and the AML1/ETO Fusion Gene: From Clinical Syndrome to Paradigm for the Molecular Basis of Acute Leukemia. , 0, , 409-424.		1
227	The Roles of the c-myc and c-myb Oncogenes in Hematopoiesis and Leukemogenesis. , 0, , 519-549.		1
228	The Role of GATA-1 and FOG in Erythroid and Megakaryocytic Differentiation. , 0, , 1-12.		1
229	RUNX1(AML1) and CBFB: Genes Required for the Development of all Definitive Hematopoietic Lineages. , 0, , 85-102.		1
230	Transcriptional Targets of the Vitamin D3 Receptor During Myeloid Cell Differentiation. , 0, , 163-180.		1
231	Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. Leukemia and Lymphoma, 2017, 58, 218-221.	1.3	1
232	Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e134.	0.4	1
233	Histone H3 G34 Tail Mutations in Cancer: Actions in <i>Cis</i> and <i>Trans</i> to Alter Chromatin and Gene Expression. Cancer Discovery, 2020, 10, 1794-1796.	9.4	1
234	The Transcriptional Program of Polycythemia Vera Revelas Altered Expression of Multiple Putative Tumor Suppressor Genes.. Blood, 2004, 104, 796-796.	1.4	1

#	Article	IF	Citations
235	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. Blood, 2014, 124, 647-647.	1.4	1
236	High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia. Blood, 2015, 126, 3251-3251.	1.4	1
237	Sprouty Proteins, A New Family of Receptor Tyrosine Kinase Inhibitors. Current Genomics, 2002, 3, 285-293.	1.6	1
238	A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.. Blood, 2005, 106, 2799-2799.	1.4	1
239	The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells.. Blood, 2005, 106, 120-120.	1.4	1
240	MMSET Dysregulates Gene Expression in Myeloma Through Global and Focal Changes in H3K36 and H3K27 Methylation. Blood, 2012, 120, 523-523.	1.4	1
241	Abstract PR09: Extracellular stiffness cues drive spatial reorganization of the genome to globally constrain RNA abundance. , 2015, , .		1
242	Epigenetic Regulation and Therapeutic Targeting in Myeloma. Blood, 2018, 132, SCI-37-SCI-37.	1.4	1
243	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. Blood, 2018, 132, 3896-3896.	1.4	1
244	Loss of KDM6A/UTX Accelerate the Development of Multiple Myeloma. Blood, 2018, 132, 1004-1004.	1.4	1
245	Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma. Blood, 2019, 134, 3757-3757.	1.4	1
246	DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Blood, 2019, 134, 535-535.	1.4	1
247	A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL. Blood, 2019, 134, 3758-3758.	1.4	1
248	The Role of BCL-6 in Normal Lymphoid System and non-Hodgkin's Lymphomas. , 0, , 271-289.		1
249	DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A. Transactions of the American Clinical and Climatological Association, 2018, 129, 24-36.	0.5	1
250	KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma. Blood, 2020, 136, 14-14.	1.4	1
251	Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1994, 34, 79-80.	2.3	1
252	E2A and the Development of B and T Lymphocytes. , 0, , 255-270.		0

#	Article	IF	Citations
253	The Role of RARÎ± and Its Fusion Partners in Acute Promyelocytic Leukemia. , 0, , 325-378.		0
254	MLL in Normal and Malignant Hematopoiesis. , 0, , 447-463.		0
255	Transcription Factors Implicated in Hematopoiesis: In Vivo Studies. , 0, , 571-591.		0
256	The Role of Pax5 (BSAP) in Early and Late B-Cell Development. , 0, , 217-228.		0
257	EVI1 Rearrangements in Malignant Hematopoiesis. , 0, , 393-408.		0
258	TEL/ETV6 Gene Rearrangements in Human Leukemias. , 0, , 425-445.		0
259	Chromosomal Translocations Associated with Disruption of Transcriptional Regulators in Leukemia and Lymphoma. , 0, , 593-597.		0
260	PU.1 and the Development of the Myeloid Lineage. , 0, , 103-115.		0
261	The Role of Retinoic Acid Receptors in Myeloid Differentiation. , 0, , 149-161.		0
262	Homeobox Gene Networks and the Regulation of Hematopoiesis. , 0, , 133-148.		0
263	The Role of Ikaros Family Genes in Lymphocyte Differentiation and Proliferation. , 0, , 181-199.		0
264	The Acetyltransferases CBP and p300: Molecular Integrators of Hematopoietic Transcription Involved in Chromosomal Translocations. , 0, , 497-517.		0
265	The LMO2 Master Gene; Its Role as a Transcription Regulator Determining Cell Fate in Leukemogenesis and in Hematopoiesis. , 0, , 483-495.		0
266	The Role of Early B-cell Factor in B-lymphocyte Development. , 0, , 313-324.		0
267	Janus Kinases and STAT Family Transcription Factors: Their Role in the Function and Development of Lymphoid Cells. , 0, , 229-254.		0
268	NF-Î°B in Cell Life and Death. , 0, , 551-570.		0
269	The Role of Octamer Factors and Their Coactivators in the Lymphoid System. , 0, , 291-311.		0
270	Role of the TAL1/SCL Transcription Factor in Normal and Leukemic Hematopoiesis. , 0, , 51-70.		0

#	Article	IF	Citations
271	CCAAT/Enhancer-Binding Proteins in Myeloid Cells. , 0, , 117-131.		0
272	Regulation of Megakaryocyte and Erythroid Differentiation by NF-E2. , 0, , 13-29.		0
273	Transcription Factors Involved in Lineage-specific Gene Expression During Megakaryopoiesis. , 0, , 31-49.		0
274	Coactivators and Leukemia: The Acetylation Connection with Translocations Involving CBP, p300, TIF2, MOZ, and MLL. , 0, , 465-481.		0
275	The Leukemogenic Function of the inv(16) Fusion Gene CBFB-MYH11. , 0, , 379-391.		0
276	What unleashes aberrant gene regulation in acute promyelocytic leukemia?. Blood, 2007, 109, 857-857.	1.4	0
277	The molecular basis of acute myeloid leukemia. , 0, , 751-768.		0
278	CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e48-e49.	0.4	0
279	CRISPR-based functional genomics landscape of genes recurrently mutated in MM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e77-e78.	0.4	0
280	Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?. Journal of Clinical Investigation, 2001, 108, 1277-1278.	8.2	0
281	Both the Activity and Stability of the Transcriptional Repressor PLZF Are Modified by the Class III Histone Deacetylase SIRT1.. Blood, 2004, 104, 360-360.	1.4	0
282	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein.. Blood, 2004, 104, 359-359.	1.4	0
283	Identification of Genes Affected during Myeloid Differentiation Induced by Valproic Acid and Retinoic Acid: The Choice of Array Pre-Processing and Normalization Algorithm Has a Critical Effect on Results.. Blood, 2004, 104, 4207-4207.	1.4	0
284	Sprouty 3. The AFCS-nature Molecule Pages, 0, , .	0.2	0
285	The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.. Blood, 2005, 106, 358-358.	1.4	0
286	Sprouty 4. The AFCS-nature Molecule Pages, 0, , .	0.2	0
287	Sprouty 1. The AFCS-nature Molecule Pages, 0, , .	0.2	0
288	Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature.. Blood, 2006, 108, 3597-3597.	1.4	0

#	Article	IF	Citations
289	A Comprehensive Genomic Approach Using Gain of Function and Loss of Function Cell Models and ChIP-on-Chip Technology Identifies Novel Promyelocytic Zinc Finger Protein Target Genes.. Blood, 2006, 108, 1407-1407.	1.4	0
290	Physical and Functional Association of PLZF with Histone Methyl Transferase and Histone Demethylase.. Blood, 2006, 108, 731-731.	1.4	0
291	The MMSET Protein Is Tightly Associated with Chromatin, Mediates Methylation of Specific Histone Residues and Forms a Complex with a Histone Demethylase.. Blood, 2006, 108, 730-730.	1.4	0
292	High Resolution SNP Arrays and Correlation with Expression Arrays Identify Novel Genomic Aberrations and Potential Disease Genes in Polycythemia Vera and Other Myeloproliferative Disorders.. Blood, 2006, 108, 359-359.	1.4	0
293	Retinoblastoma Protein and the Leukemia-Associated PLZF Transcription Factor Interact To Repress Target Gene Promoters.. Blood, 2007, 110, 1240-1240.	1.4	0
294	Comprehensive Genomic Screens Reveal Multiple Modes of Action of the PLZF-RAR-Î± Oncoprotein. Blood, 2008, 112, 686-686.	1.4	0
295	PLZF-RARÎ± Utilizes the Histone Methyl Transferase G9a/GLP and the Histone Demethylase LSD1 to Repress RARÎ± Target Genes and Block Myeloid Differentiation. Blood, 2008, 112, 198-198.	1.4	0
296	NFIB: A Gene Consistently Upregulated in MPD and Frequently Co-Amplified with JAK2V617F Augments Growth of Erythropoietin Dependent Cells. Blood, 2008, 112, 3727-3727.	1.4	0
297	Genome-Wide Chromatin Immunoprecipitation and Gene Expression Analysis Indicates That MMSET Is a Transcriptional Repressor in Vivo. Blood, 2008, 112, 627-627.	1.4	0
298	Spry1 Plays Selective Hematopoietic Roles as An Erythropoietin - Modulated Positive Regulator of Erythropoiesis.. Blood, 2009, 114, 777-777.	1.4	0
299	The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.. Blood, 2009, 114, 675-675.	1.4	0
300	Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors. , 2009, , .		0
301	Abstract 1126: Gene expression profiling reveals that WT1 and WTX control cell growth through similar gene networks but different specific genes. , 2010, , .		0
302	Mir-9 Is Aberrantly Expressed In MPN Patients and Accelerates Erythropoietic Cell Growth and Differentiation. Blood, 2010, 116, 1983-1983.	1.4	0
303	Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors. , 2011, , .		0
304	MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response,. Blood, 2011, 118, 3475-3475.	1.4	0
305	MMSET Stimulates Myeloma Cell Growth Through MicroRNA-Mediated Modulation of c-MYC. Blood, 2011, 118, 469-469.	1.4	0
306	Abstract 1046: The histone methyl transferase MMSET/WHSC1 promotes an epithelial-mesenchymal transition and invasive properties of prostate cancer. , 2012, , .		0

#	Article	IF	Citations
307	Abstract 2165: Sprouty loss leads to aberrant regulation of receptor tyrosine kinase signaling pathways and accelerates mammary tumorigenesis. , 2012, , .		0
308	Aberrant Histone Methylation in Myeloma: What Are the Rules?. Blood, 2012, 120, SCI-5-SCI-5.	1.4	0
309	MMSET/WHSC1 Enhances DNA Damage Repair Leading To An Increase In Resistance To Chemotherapeutic Agents. Blood, 2013, 122, 808-808.	1.4	0
310	Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells. , 2014, , .		0
311	Abstract 2344: 3D extracellular stiffness cues drive localized changes in gene expression. , 2014, , .		0
312	Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition. , 2014, , .		0
313	Abstract IA26: Aberrant histone methylation in multiple myeloma.. , 2015, , .		0
314	Abstract B32: Loss of the histone demethylase UTX alters the gene expression prolife and contributes to the malignant phenotype of multiple myeloma cells.. , 2015, , .		0
315	FQI1: a transcription-methylation switch for cancer. Oncotarget, 2017, 8, 12536-12537.	1.8	0
316	Abstract 343: Targeting DNA replication as a therapeutic strategy for acute myeloid leukemia with DNMT3A mutations. , 2018, , .		0
317	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. Blood, 2018, 132, 1367-1367.	1.4	0
318	Abstract 1922: MYB mimic peptides targeting human and murine MYB-NFIB positive tumor cells. , 2019, , .		0
319	Abstract 378: HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling. , 2019, , .		0
320	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. Blood, 2019, 134, 318-318.	1.4	0
321	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. Blood, 2021, 138, 1612-1612.	1.4	0
322	Functional CRISPR Screening Identifies Ptprg As a Driver of Migration and Adhesion in NSD2-E1099K ALL. Blood, 2021, 138, 1149-1149.	1.4	0
323	Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation. Blood, 2021, 138, 3297-3297.	1.4	0
324	Adenylate Kinase 2 Is a Selective Multiple Myeloma Cell Dependency That Is Preferentially Essential in NSD2-Overexpressing Cells. Blood, 2021, 138, 1586-1586.	1.4	0

#	Article	IF	Citations
325	Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma. Blood, 2021, 138, 1589-1589.	1.4	0
326	Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications. Blood, 2020, 136, 40-40.	1.4	0
327	Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications. Blood, 2020, 136, 3-4.	1.4	0
328	NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice. Blood, 2020, 136, 3-4.	1.4	0
329	Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma. Blood, 2020, 136, 31-31.	1.4	0
330	Abstract 3800: HDAC8 regulates plasticity and escape from therapy in BRAF mutant melanoma. , 2019, , .		0
331	The Role of PU.1 in B-lymphocyte Development and Function. , 0, , 201-216.		0